Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
You may also be interested in...
Shire Emphasizes The GI Space In Its Bid For Movetis
Only five years ago, Shire's specialty pharma business consisted of one product, Adderall XR, one market, the U.S., and one patient type - children. Multiple generics companies had filed ANDAs, however, and the company was looking to broaden its base
As Some VCs Run On Empty, Others Are Topping Off The Tank
New money is increasingly hard to come by for life sciences venture capital firms. Start-Up tracks VCs to determine which firms have older vintage funds and which have plenty of fresh capital to invest.
Boehringer Ingelheim Joins The Corporate Venture Party
In late March, Boehringer Ingelheim GMBH formally unveiled its $134 million corporate venture fund, a strategically-focused effort that will invest in areas believed to be important to the privately-held German pharma's future growth, including RNA silencing, stem cells, and next generation vaccine, protein, and antibody technologies.